President’s Cancer Panel
SaneVax: Despite the fact that medical consumers in the United States have virtually rejected the idea of replacing the already proven safe and effective method of controlling cervical cancer with HPV vaccines which will not be proven to prevent cervical cancer for decades, the President’s Cancer Panel is pushing for higher HPV vaccine uptake. The members of this panel do not seem to understand vaccines carry an inherent risk for some recipients. Why would any medical consumer in their right mind subject themselves or their children to the risks of using Gardasil or Cervarix when there is already a safe and effective means of detecting and treating pre-cancerous lesions prior to them developing into cancer?
According to a recent article in FIERCE PHARMA:
The strategies proposed by the panel are intended to address many of the oft-cited barriers to widespread use of HPV vaccines. For example, CDC estimates that if Gardasil or GlaxoSmithKline’s ($GSK) Cervarix was administered whenever an adolescent girl visited their healthcare provider for another vaccine, more than 90% of the demographic would have received at least one dose of a HPV vaccine. The panel wants to reduce these missed opportunities by having CDC develop communication strategies for physicians. Use of electronic systems to track vaccinations is also encouraged.
What is wrong with this picture? Why is the government marketing vaccines that are not proven to be effective for their stated purpose?
The President’s Cancer Panel is pushing for increased use of Merck’s and GSK’s HPV vaccines
By Nick Paul Taylor
The reasons for low uptake of human papillomavirus (HPV) vaccines have been well researched and widely discussed by academia and government agencies, yet this knowledge has done nothing to increase adoption. Now, the President’s Cancer Panel has weighed in to give momentum to a public health campaign it views as a “profound opportunity” to prevent cancer.